Abstract
Previous studies have detected high levels of matrix metalloproteinases (MMPs) in metastatic prostate cancer. In this study, we recruited 40 patients with prostate cancer (PCa): 20 presented organ-confined carcinoma and 20 had metastatic cancer. We also recruited 40 subjects for control groups, 20 with benign prostate hyperplasia (BPH) and 20 healthy males with similar characteristics. All of the patients were monitored at the beginning (time 0) and after 90 days. We analyzed the plasma concentrations of MMP-2, MMP-9, MMP-13, TIMP-1 and the enzyme activity of MMP-2 and MMP-9,using specific ELISA tests. The plasma concentrations of MMP-2, MMP-9 and MMP-13 were higher in PCa patients with metastasis than in the other groups, and in these patients decreased markedly after therapy began. For MMP-2 and MMP-9, greater differences were observed in enzyme activity than in plasma concentrations. TIMP-1 was reduced in PCa patients with metastasis, even if the intergroup differences were not statistically significant. Our results suggest that the plasma concentration and activity of MMPs, in association with PSA determination, could play a role in diagnosis, monitoring therapy and evaluating malignant progression in PCa.
Similar content being viewed by others
References
Young TN, Rodriguez GC, Reinhart AR, Bast RCJr, Pizzo SV, Stack M (1996) Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase. Gynecol Oncol 62: 89
Kugler A, Hemmerlein B, Thelen P, Kallerhff M, Radzun H-J, Ringert R-H (1998) Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J Urol 160: 1914
Crawford HC, Matrisian LM (1995) Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression. Invasion Metastasis 14: 234
Jung K, Novak L, Lein M, Priem F, Schnorr D, Loening SA (1997) Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinasa-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer. Int J Cancer 74: 220
Baker T, Tickle S, Wasan H, Docherty A, Isenberg D, Waxam J (1994) Serum metalloproteinases and their inhibitors: markers for malignant potential. Brit J Cancer 70: 506
Murray GI, Duncan ME, O’Neil P, Melvin WT, Fothergill E (1996) Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 2: 461
Gohji K, Fujimoto N, Fujii A, Komiyama T, Okawa J, Nakajiama M (1996) Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinase-2 ratio in recurrence of urothelial cancer after complete resection. Cancer Res 56: 3196
Kanayama H, Yokota K, Kurokawa Y, Murakami Y, Nishitani M, Kagawa S (1996) Prognostic value of matrix metalloproteinase-2 and tissue inhibitor of metallopreteinase-2 expression in bladder cancer. Cancer Res 56: 3196
Lindsay CK, Thorgeiesson UP,Tsuda H, Hirohashi S (1997) Expression of tissue inhibitor of metalloproteinase-1 and type IV collagenase/gelatinase messenger RNAs in human breast cancer. Human Pathol 28: 359
Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S (1980) Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67
Boag AH, Young ID (1994) Increased expression of the 72 kDa type IV collagenase in prostatic adenocarcinoma. Am J.Pathol 144: 585
Pendas AM, Uria JA, Jimenez MG, Balbin M, Freije JP, Lopez-Otin C (2000) An overview of collagenase-3 expression in malignant tumors and analysis of its potential value as a target in antitumor therapies. Clin Chim Acta 291: 137
Wood M, Fudge K , Mohler JL, Frost AR, Garcia F, Wang M, Stearns ME (1997) In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis 15: 246
Oesterling JE, Chan DW, Epstein JI, Kimball AWJr, Bruzek DJ, Rock RC, Brendeer CB, Walsh PC (1998) Prostate specific antigen in the preoperative end postoperative evaluation of localized prostate cancer treated with radical prostatectomy. J Urol 139: 766
Hadson MA, Bahnsonn RR, Catalona WJ (1989) Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 142: 1011
Catalona WJ, Smith DS, Rathiff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL (1991) Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324: 1156
Glenski WJ, Malek RS, Myrtle JF, Oeslerling JE (1992) Sustained substantially increased concentration of prostate specific antigen in the absence of prostatic malignant disease: an unusual clinical scenario. Mayo Clin Proc 67: 349
Chu TM (1998) Prostate specific antigen. In: Sell S (ed) Serological cancer markers. Humana Press, Florence, p 99
Albertsen PC (1998) Patologia della prostata nell’anziano: il carcinoma. Minuti 1998: 21
Jung K, Nowak L, Lein M, Priem F, Schnorr D, Loening SA (1997) Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer. Int J Cancer 74:220
Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR (1998) Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 58: 1395
Hamdy FC, Fadlon EJ, Cottam D et al. (1994) Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 69: 177
Lichtinghagen R, Musholt PB, Stephan C et al. (2003) mRNA expression profile of matrix metalloproteinases and their tissue inhibitors in malignant and non-malignant prostatic tissue. Anticancer Res 23: 2617
Kanoh Y, Akahoshi T, Ohara T et al. (2002) Expression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer. Anticancer Res 22: 1813
Lichtinghagen R, Musholt PB, Lein M et al. (2002) Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. Eur Urol 42: 398
Ross JS, Kaur P, Sheehan CE (2003) Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod Pathol 16: 198
Brehmer B, Biesterfeld S, Jakse G (2003) Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue. Prostate Cancer Prostatic Dis 6: 217
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Morgia, G., Falsaperla, M., Malaponte, G. et al. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res 33, 44–50 (2005). https://doi.org/10.1007/s00240-004-0440-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00240-004-0440-8